<DOC>
	<DOCNO>NCT01249547</DOCNO>
	<brief_summary>This open-label , single arm , phase 2 clinical trial evaluate activity safety single-agent axitinib recurrent metastatic NPC patient fail least one line platinum base chemotherapy .</brief_summary>
	<brief_title>Nasopharyngeal Carcinoma ( NPC ) Axitinib</brief_title>
	<detailed_description />
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Histologically confirm diagnosis nasopharyngeal carcinoma ( NPC ) ( either initial diagnosis recurrence ) . Patients recurrent metastatic NPC progress follow one line prior platinumbased chemotherapy . Disease must amenable potentially curative radiotherapy surgery . Measurable disease accord RECIST . Age 18 ; ECOG performance 0 1 . Adequate bone marrow , renal hepatic reserve . Presence local recurrence Presence neck lymph node recurrence invade vascular structure ; Presence central lung lesion involve major blood vessel ; History hemoptysis epistaxis within 4 week ; Preexisting uncontrolled hypertension define 140/90 mmHg despite adequate medical therapy ; Gastrointestinal abnormality , include inability take oral medication malabsorption syndrome ; Concurrent use anticipate need treatment know potent CYP3A4 inhibitor CYP3A4 /CYP1A2 inducer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>